Biocon Limited · NSE:BIOCON
Biocon — Q1 FY19 Earnings Presentation
29 slides from Biocon's earnings presentation, Sep 2, 2018
Slide 1: Exchange submission letter for investor presentation
Date of Submission: September 02, 2018 To To The Secretary The Secretary Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Department of Corporate Services Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Mumbai – 400 050 Dalal Street, Mumbai –
Slide 2: Slide 2
Slide 3: Biocon Limited Investor Presentation September 2018
Biocon Limited BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM Investor Presentation September 2018
Slide 4: Safe Harbor
Safe Harbor Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.
Slide 5: Agenda
Agenda Our Journey Business & Financial Highlights • Small Molecules Our Business • Biologics • Branded Formulations • Research Services - Syngene Business Holding Structure & Five Year Financials Enduring Edge
Slide 6: Biocon: Asia's Leading Biopharma Company
Biocon: Asia’s Leading Biopharma Company Our Vision To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe Our Mission To be an integrated Biotech enterprise of global distinction Our Values Integrity & Ethical
Slide 7: Committed to Affordable Access
Committed to Affordable Access Aiming to develop products that can potentially benefit a billion patients Enduring Edge
Slide 8: The Biocon Journey: A Continuous Evolution
The Biocon Journey: A Continuous Evolution 1978-1999 2000-2004 2005-2009 2010-2015 2016 and beyond Focused on Biosimilar Transforming Building the Trastuzumab global An Enzymes into a Base Business approved by US FDA; development and Company Biopharma and expertise in Biosimilar PEG-GCSF strategic g
Slide 9: Key Innovations: Making a Difference
Key Innovations: Making a Difference Ogivri™, first Second Novel biosimilar Biologic Launches (Insulin Glargine Trastuzumab prefilled disposable approved by US KRABEVA® First Novel pen) FDA in India Biologic Launches Launches Basalog One™ ALZUMAb™ Launches (Itolizumab) Launches BASALOG® (Insulin Gla
Slide 10: Business & Financial Highlights
Business & Financial Highlights Enduring Edge
Slide 11: Business: Recent Highlights
Business: Recent Highlights Fulphila™, co-developed by Biocon and Mylan, becomes the first biosimilar Pegfilgrastim to be approved and launched in the U.S. Biocon is the first Company from India to have two biosimilars approved by the U.S. FDA. Biocon’s sterile Drug Product manufacturing facility in
Slide 12: Revenue Highlights
Revenue Highlights All Figures in ₹ Million except % Growth Growth Particulars Q1 FY19 Q1 FY18 FY18 FY17 (%) (%) - Small Molecules 4,001 3,629 10 15,077 16,405 (8) - Biologics 2,497 1,839 36 7,702 7,018 10 - Branded Formulations 1,473 1,304 13 6,115 5,489 11 - Syngene (Research Services) 4,060 2,911
Slide 13: Financial Summary
Financial Summary All Figures in ₹ Million except % Growth Growth Particulars Q1 FY19 Q1 FY18 FY18 FY17 (%) (%) Revenue 11,926 9,877 21 43,359 40,787 6 EBITDA 3,066 2,461 25 10,353 11,366 (9) Net Profit 1,197 813 47 3,724 6,121 (39) R&D Expenses in 442 582 (24) 2,158 2,662 (19) P&L Gross R&D Spends
Slide 14: Our Business
Our Business - aS Enduring $ Biocon | Edge gouges Wwe : tid
Slide 15: Business Segments
Business Segments Branded Formulations Finished Dosage Business in India & Overseas Small Molecules Research Services Syngene Differentiated APIs CRO offering integrated service platform & Generic Formulations for novel molecule drug discovery & development for small & large molecules Biologics Nove
Slide 16: Small Molecule: APIs & Generic Formulations
Small Molecule : APIs & Generic Formulations Differentiated APIs Current Constituents Portfolio Product Portfolio leverages core fermentation technology strengths Simvastatin, Pravastatin, Atorvastatin, Statins Rosuvastatin, & Fluvastatin. Among world’s largest manufacturers of statins & immunosupre
Slide 17: Biologics: Biosimilars & Novel Biologics
Biologics: Biosimilars & Novel Biologics Biosimilars Novel Biologics 15+ years of experience Creating market leadership is developing biologics in Innovation e.g., Insulin with multiple biosimilars Tregopil, Itolizumab commercialized globally Strong scientific and Pipeline includes oral technical ca
Slide 18: Strategic Partnership with Mylan for Biosimilars: Insulins & mAbs
Strategic Partnership with Mylan for Biosimilars: Insulins & mAbs BIOCON MYLAN • Global-scale, complex biologics • Strength in Regulatory/ filings manufacturing capabilities strategy • Facilities accredited by • Strong commercialization international regulatory agencies capability in US and EU. • De
Slide 19: Strategic Partnership with Sandoz for next generation Biosimilars
Strategic Partnership with Sandoz for next generation Biosimilars Deal Structure Portfolio addresses next wave of immunology and oncology biosimilars Both companies share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of biosimilars Costs & prof
Slide 20: Status of Biocon's Global Biosimilars Portfolio
Status of Biocon’s Global Biosimilars Portfolio Partner Therapeutic Area Molecule Status Approved in U.S. Under review in EU, Canada Oncology Trastuzumab and Australia. Launched in emerging markets Approved in EU & Australia. Under review in U.S. and Canada. Launched in Japan* Diabetes Insulin Glarg
Slide 21: Biocon Well Placed in Competitive Global Landscape
Biocon Well Placed in Competitive Global Landscape Molecule Biosimilar Development Pipeline@ Phase I Phase 3 Regulatory Submission Approved/ Marketed EMA FDA EMA FDA pegfilgrastim DRL, Pfizer, Adello, Biocon, Apotex, Coherus, Apotex, Coherus (+CHMP) Biocon Lupin, Zydus Richter, Sandoz, Cinfa, Sandoz
Slide 22: Biosimilars Manufacturing: Building Global Scale
Biosimilars Manufacturing: Building Global Scale Biocon Malaysia: Asia’s largest integrated insulins manufacturing facility Biocon’s First Manufacturing expansion overseas in Iskandar, Johor. Investment of over US$275mn in the first phase. Sales commenced in Emerging Markets; include OTA award by Mi
Slide 23: Novel Molecules - Pipeline & Therapeutic Area Focus
Novel Molecules - Pipeline & Therapeutic Area Focus Insulin Tregopil * India Phase II/III in DIABETES First-in-Class Oral, Prandial Insulin T2D commenced Itolizumab* IND Ready Novel, humanized CD6 Antibody BVX-20# INFLAMMATION Novel, humanized CD20 Antibody Path to IND mapped QPI-1007$ Phase III in
Slide 24: Novel Molecules: Progressing to key milestones
Novel Molecules: Progressing to key milestones Asset Details Insulin Tregopil USP: Oral, Ultra Rapid-Acting Post- prandial glycemic control; Liver specific- portal delivery, Weight neutral Phase II/III Ongoing Safety & tolerability established in Phase 1 studies in US – DDI, Food Effect, PK/PD Dat
Slide 25: Branded Formulations: India & UAE
Branded Formulations: India & UAE Specialty business with regional ambitions; strong value builder for Biocon. Biologics-led specialty products focused on chronic therapy areas. Comprehensive offering of products, patient and physician support programs INDIA UAE India’s largest Insulins & leading On
Slide 26: Research Services Business: Syngene
Research Services Business: Syngene One of leading India based CROs, a global high growth CRO company Offers an integrated drug discovery and development platform for both small and large molecules backed by best-in-class bioinformatics services Focus on novel molecular entities Wide spectrum of ser
Slide 27: Business Holdings Structure
Business Holdings Structure$ Biocon Limited, India Biocon SA, Switzerland (100%) Small Molecules & ANDA, Novels, Biocon FZ LLC Branded Biocon Pharma, (100%)/ Formulations India (100%) NeoBiocon, UAE (49%) Biocon Healthcare Biocon Pharma, Sdn Bhd (100%) USA (100%) Syngene, India Biocon Biologics, UK
Slide 28: Five Year Financials
Five Year Financials All Figures in ₹ Million except EPS Business Segment FY13 FY14 FY15 FY16 FY17$ Biopharmaceuticals 18,705 21,382 22,367 23,908 26,259 - Biopharma 15,231 17,468 18,071 19,534 20,764 - Branded Formulations 3,474 3,914 4,296 4,374 5,495 Contract Research 5,572 7,146 8,225 10,599 11,
Slide 29: Investor Relations contact
Investor Relations contact: Saurabh Paliwal Tel : +91 80 6775 2040 Email: investor.relations@biocon.com For further information, please visit www.biocon.com